You are here: Industry Insights > Aimmune

News List

Aimmune’s peanut allergy med Palforzia wins EU approval pharmatimes
December 22, 2020
The European Commission (EC) has approved Aimmune Therapeutics’ Palforzia, making it the first treatment for peanut allergy in the EU, according to the firm.
Aimmune’s peanut allergy med moves toward EU approval pharmatimes
October 22, 2020
Aimmune has been granted a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its drug Palforzia as a treatment of peanut allergic patients aged 4-17 years.
Nestlé plunks down $2.1B to acquire Aimmune and blockbuster hopeful peanut allergy med fiercepharma
September 01, 2020
Swiss giant Nestlé has had a mixed bag in its dive into pharma, including a disappointing exit from prescription meds last year.
Phase III results move Aimmune’s peanut allergy drug closer to EU market pharmatimes
March 28, 2019
Aimmune has announced the results from its Phase III European clinical trials for AR101, the company’s investigational oral biologic drug designed to help protect patients from severe allergic reactions in case they are accidentally exposed to peanut.
Aimmune publishes phase III data for peanut allergy drug pharmaceutical
November 21, 2018
Aimmune has published the data from its phase III PALISADE clinical trial into AR101, a biologic immunotherapy indicated for desensitisation of patients with peanut allergies in the New England Journal of Medicine.